Oculis (NASDAQ:OCS) Sees Large Volume Increase

Shares of Oculis Holding AG (NASDAQ:OCS) saw unusually-strong trading volume on Tuesday . Approximately 52,187 shares traded hands during mid-day trading, an increase of 11% from the previous session’s volume of 47,215 shares.The stock last traded at $13.25 and had previously closed at $12.73.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on OCS. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of Oculis in a research note on Tuesday, March 19th. HC Wainwright reduced their price objective on shares of Oculis from $29.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, April 24th. Wedbush reissued an “outperform” rating and issued a $29.00 price objective on shares of Oculis in a research note on Wednesday, March 6th. Finally, Robert W. Baird cut their target price on Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 19th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $29.14.

Oculis Stock Down 1.7 %

The business’s 50 day moving average is $11.87 and its 200 day moving average is $11.28. The company has a quick ratio of 5.29, a current ratio of 5.29 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.04. The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.28 million. On average, sell-side analysts predict that Oculis Holding AG will post -1.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Wolverine Asset Management LLC acquired a new stake in Oculis in the 3rd quarter worth approximately $77,000. Compagnie Lombard Odier SCmA lifted its stake in shares of Oculis by 47.3% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after buying an additional 30,750 shares during the period. abrdn plc purchased a new stake in shares of Oculis during the fourth quarter valued at $15,980,000. Finally, Searle & CO. purchased a new stake in shares of Oculis during the fourth quarter valued at $112,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.